Clinical Trials
Positive Results from CPP-115 Trial
May 22, 2012 11:17 am | News | CommentsCatalyst Pharmaceutical Partners Inc. announced positive results from a Phase 1a study to evaluate the safety, tolerability and pharmacokinetic profile of CPP-115.
NovaBay Begins Enrolling NVC-422 Patients
May 22, 2012 11:09 am | News | CommentsNovaBay Pharmaceuticals Inc. has enrolled the first patients in its Phase 2b clinical study to evaluate its lead compound NVC-422, for treating adenoviral conjunctivitis.
Nexavar Flunks Lung Cancer Trial
May 22, 2012 10:29 am | News | CommentsA cancer treatment from Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc. failed to improve overall survival in patients with advanced cases of lung cancer.
Drug Combo Tackling Solid Tumors
May 18, 2012 11:09 am | News | CommentsCancer Research UK's Drug Development Office has begun a trial of a drug combination in patients with advanced solid tumors and in patients with non-small cell lung cancer.
Phase 2 Results for EP-101 Positive
May 18, 2012 10:56 am | News | CommentsElevation Pharmaceuticals Inc. announced positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease.
Positive Results for Theraclone Flu Treatment
May 17, 2012 11:25 am | News | CommentsTheraclone Sciences Inc. announced positive data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, for the treatment of influenza A infections.
Ark Readies Phase 2 Study
May 17, 2012 11:00 am | News | CommentsArk Therapeutics Group plc has completed the dose ranging Phase 1 section of the academic study of Ark’s VEGF-D adenoviral vector treatment for refractory angina.
GAL-021 Counteracts Respiratory Depression
May 15, 2012 10:49 am | News | CommentsGalleon Pharmaceuticals announced that GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase 1 study.
Juggling Clinical Trial Supplies
May 15, 2012 9:54 am | by Ganesh Swaminath, PhD, General Manager, Pharmaceuticals, Global Healthcare,and Life Sciences Practice; Wipro Technologies, Chennai, India | Articles | CommentsClinical development is an integral part of launching new drugs to market, and is comprised mainly of conducting clinical trials and submitting the data for approval.
NovaDigm Wraps Up Second Study
May 14, 2012 11:31 am | News | CommentsNovaDigm Therapeutics announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.
Positive Data from Schizophrenia Trial
May 14, 2012 11:28 am | News | CommentsOtsuka Pharmaceutical Co. Ltd. and H. Lundbeck A/S announced results from a Phase 3 clinical trial evaluating aripiprazole for the treatment of adults with schizophrenia.
Positive Results from Fissure Trial
May 14, 2012 11:24 am | News | CommentsVentrus Biosciences Inc. reported positive results from its Phase 3 clinical trial of diltiazem hydrochloride cream in patients with anal fissures.
Promethera Treating Patients with HepaStem
May 14, 2012 11:21 am | News | CommentsPromethera Biosciences has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology, HepaStem.
AesRx Starts Aes-103 Trial
May 14, 2012 11:17 am | News | CommentsAesRx LLC has begun a Phase 1/2a clinical trial of Aes-103 in patients with sickle cell disease. This trial is part of an ongoing collaboration with the National Institutes of Health.
TapImmune Beginning Phase 1 Trial
May 10, 2012 10:58 am | News | CommentsTapImmune Inc. has announced that following recent IRB approval a Phase 1 clinical trial on a novel set of HER2/neu Class II antigens will start at Mayo Clinic.
FDA Panel Backs Tofacitinib
May 10, 2012 10:14 am | by Matthew Perrone | News | CommentsFederal health advisers said that a first-of-a-kind drug from Pfizer appears to be safe and effective for patients with rheumatoid arthritis.
GTx Restarting Mid-Stage Trial
May 9, 2012 10:45 am | News | CommentsGTx Inc. announced that regulators are allowing it to restart clinical testing of its prostate cancer drug Capesaris. The company said it will start a new mid-stage trial of Capesaris during the third quarter of 2012.
CureXcell Meets Goals in Late-stage Study
May 8, 2012 11:11 am | News | CommentsMacrocure has achieved positive results for a Phase 4 trial of its lead product, CureXcell, for the treatment of hard-to-heal ulcers in a community care setting.
HT-100 Receives Orphan Status
May 8, 2012 11:00 am | News | CommentsHalo Therapeutics LLC announced that the European Commission has granted orphan medicinal product designation to HT-100 for the treatment of Duchenne muscular dystrophy.
Dalcetrapib Testing Halted
May 8, 2012 10:40 am | by Linda A. Johnson | News | CommentsA second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing.
Study Compares Actemra Formulations
May 7, 2012 11:18 am | News | CommentsGenentech announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of subcutaneous Actemra to intravenous Actemra.
Pfizer Halts Lyrica Study
May 7, 2012 10:56 am | News | CommentsThe world's largest drugmaker, Pfizer, halted a late-stage study of its second-best selling drug, Lyrica, as a possible treatment for a nerve pain in HIV patients.
AVEO Releases Phase 2 Data
May 3, 2012 11:29 am | News | CommentsA Phase 2 study has compared a combination of ficlatuzumab and gefitinib to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer.
Gilead Begins GS-1101 Trial
May 3, 2012 11:16 am | News | CommentsGilead Sciences Inc. announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.
Quotient Receives Enterion Approval
May 2, 2012 11:42 am | News | CommentsQuotient Clinical has received approval of the final patent for its Enterion technology. This completes a portfolio of eight granted patents across North America and Europe.
